Home|Journals|Articles by Year

Directory for Medical Articles

Original Research

RMJ. 2021; 46(3): 518-521

Prevalence of ESBLs secreting and carbapenem-resistant E. coli from urinary tract infection

Farhina Nasir, M. Irfan Khan, Shahid Kashif, Fakhur Uddin, Amber Naseer, Shaheem Masood.


Objective: To determine the prevalence of ESBL producing and carbapenem-resistant E. coli in UTI from a tertiary care Hospital.
Methodology: A total of 320 mid-stream urine samples were collected from patients suspected for UTI at the urology department of Jinnah postgraduate medical center, Karachi. Cystine lactose electrolyte deficient agar was used for culture. Antimicrobial susceptibility was determined by disc diffusion method. ESBL production was determined by double disc synergy test (DDST). The carbapenem resistance was determined by minimal inhibitory concentration method by Etest.
Results: Prevalence of UTI was higher (165/230, 71.7%) in age group of 21-40 years. The mean age of UTI patients was 38.75±15.01 years with dominancy of females (55.3%). Out of 320 samples, 256 (80%) were culture positive. E. coli was the most prevalent uropathogen 139(54.3%) followed by 59(23%), 24(9.4%), and 22(8.6%), Klebsiella, Proteus, and Pseudomonas species, respectively. E. coli showed highest resistance to ampicillin 87%, and lowest against meropenem (4.3%). Out of 139 E. coli, 92(66.2%) were ESBL producers, resistant to carbapenem was higher (5.03%) in ESBL producing E. coli in compassion to non- ESBL producers (1.43%).
Conclusion: The prevalence of ESBL producing E. coli was higher and carbapenem-resistant E. coli in urinary tract infections in community is still at lower prevalence.

Key words: UTI, carbapenem-resistant, E. coli.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.